Paragon 28, Inc. (NYSE: FNA) saw its stock price surge 5.1% in Friday's intraday trading session, following the release of its impressive third-quarter results and analysts' positive outlook for the company.
The medical device company reported better-than-expected revenue of $62 million, beating analysts' forecasts by 2.9%. Additionally, Paragon 28's earnings loss of $0.15 per share was narrower than anticipated, outperforming estimates by 3.8%.
Analysts have responded favorably to the company's performance, with the consensus price target of $14.40 implying further upside potential. Notably, some analysts have set bullish price targets as high as $20 per share, indicating confidence in Paragon 28's growth prospects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。